# Autophagy Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autophagy-sciences

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.autophagysci.com
- Total disclosed funding: $6.8M
- Latest round: Series A (Jan 19, 2021)
- Investors on record: 3

## About

Based in South Korea, Autophagy Sciences is a biotechnology firm focused on developing innovative medicines that harness the process of autophagy to address challenging diseases.Autophagy Sciences, founded in 2016 and headquartered in Seoul, South Korea, specializes in creating therapeutic solutions based on autophagy. The company secured a Series A funding round of KRW 7.5 billion on January 19, 2021, with major investments from Cloud IB Investment, Industrial Bank of Korea, and Kolon Investment, bringing the total amount raised to KRW 7.5 billion and the company's valuation to KRW 20 billion. The founder and CEO, Jung-joo Kim, is an experienced leader in the biotech sector.Autophagy Sciences specializes in the development of innovative medicines based on the phenomenon of autophagy. The company’s core offerings focus on a diverse pipeline aimed at treating difficult-to-manage diseases, specifically targeting conditions that are currently underserved by existing therapeutics. These products provide patients with new treatment opportunities, ultimately improving their quality of life, and the company serves a global client base including healthcare providers, research institutions, and pharmaceutical partners across various markets.The revenue model of Autophagy Sciences is structured around collaborations and partnerships with other entities in the pharmaceutical and biotech sectors. The company engages in B2B transactions, providing its therapeutic pipeline to research institutions and healthcare organizations seeking innovative treatment solutions. Partnerships may involve contractual agreements for research and development services, licensing arrangements, or revenue-sharing models based on the commercialization of developed therapies, with pricing structures designed to align with the value brought to end users.In January 2021, Autophagy Sciences raised KRW 7.5 billion to fund clinical trials and establish research institutes. The company is also considering selecting an underwriter for an IPO next year. Future plans include the launch of new products aimed at addressing unmet medical needs and the expansion into new markets, although specific regions targeted for this expansion have not been disclosed.

## Funding rounds

- Series A, Jan 19, 2021, $6.8M — Industrial Bank of Korea, Kolon Investment, Cloud IB Investment

## Investors

- Industrial Bank of Korea — Series A
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A
- Cloud IB Investment (https://capitalatlas.ai/funds/cloud-ib-investment) — Series A